Maravai LifeSciences Q2 Earnings Call Highlights

Key Points

• Q2 revenue rose 9% to $51.4 million, led by 12% growth at TriLink and 3% growth at Cygnus. TriLink benefited from stronger discovery mRNA demand, a 55% increase in GMP consumables, and record additions of 67 discovery mRNA customers.
• Profitability improved sharply as adjusted gross margin expanded to 58.9% and adjusted EBITDA reached $8.7 million, up more than $19 million year over year. Maravai also reduced borrowings to about $150 million and extended its debt maturity to 2032.
• Maravai maintained 2026 revenue guidance of $205 million to $215 million but raised adjusted EBITDA guidance to $33 million-$35 million. Management cited potential timing variability for large CDMO projects and GMP orders while forecasting continued high-teens TriLink growth and low- to mid-single-digit Cygnus growth.

Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.

Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CEO Bernd Brust said the performance extended momentum established in the first quarter, led by demand in TriLink Biotechnologies’ mRNA-related products and continued growth at Cygnus Technologies.

TriLink revenue increased 12% year over year, while Cygnus revenue rose 3%, its fifth consecutive quarter of growth, according to the company. TriLink accounted for 67% of total revenue during the quarter, and Cygnus represented the remaining 33%.

mRNA and GMP Consumables Drive TriLink Growth

Within TriLink, discovery mRNA revenue increased 17% year over year, supported by demand from larger preclinical programs. GMP consumables revenue rose 55%, driven by large CleanCap clinical orders and the company’s first GMP enzyme order. Maravai said it recorded no COVID-related GMP revenue in the second quarter.

Brust said the company views its discovery mRNA business as an early indicator of future clinical-grade demand, because customers may progress from research and preclinical work into clinical development and subsequently require GMP materials.

TriLink added 67 new discovery mRNA customers during the quarter, a record for the company, while its e-commerce platform generated record quarterly revenue. Management said the online channel has supported customer acquisition and ordering automation, particularly among earlier-stage research customers.

The company also said four new customers transitioned to GMP products in the second quarter, bringing the total to six for the year. Management continues to expect nine customer transitions to GMP during 2026, while noting there could be upside depending on customer timing.

Maravai introduced a GMP-grade enzyme portfolio during the quarter and shipped its first enzyme order. It also plans to launch GMP-grade ModTail later in 2026, though Brust said the company does not expect orders for that product until 2027. More than 125 customers were actively using ModTail one year after its commercial launch, the company said.

Cygnus Delivers Recurring Revenue Growth

Cygnus generated $11.4 million in adjusted EBITDA during the quarter, representing a 68% margin. The business benefited from demand for host cell protein, or HCP, and ELISA kits, as well as distributor-order timing in China, CFO Raj Asarpota said.

Cygnus also launched a residual protein A Mix-N-Go kit and continued investing in mass spectrometry analytical services. Management said the services business has a longer sales cycle but is seeing growing customer engagement and repeat business. The company did not disclose specific revenue contribution from its MockV product line, describing it as a small but growing contributor to Cygnus.

Margins Improve as Cost Actions Take Effect

Maravai’s adjusted gross margin expanded by more than 1,600 basis points from a year earlier to 58.9%. Adjusted EBITDA was $8.7 million, an improvement of more than $19 million year over year, which management attributed to stronger revenue, favorable mix toward higher-margin GMP and discovery mRNA products, and operating-expense discipline.

The company reported a GAAP net loss before non-controlling interest of $21.6 million, compared with a $69.8 million loss in the second quarter of 2025. Basic and diluted loss per share was $0.08, improving from a $0.27 loss per share a year earlier. Adjusted loss per share was $0.02, compared with $0.08 in the prior-year period.

Maravai ended the quarter with $70.1 million in cash and $147.1 million in debt. In June, the company refinanced its term loan, reduced borrowings to about $150 million, and extended the debt maturity to 2032.

Revenue Outlook Maintained; EBITDA Forecast Raised

Maravai maintained its 2026 revenue guidance of $205 million to $215 million, representing expected growth of 10% to 16% over 2025. The company continues to expect TriLink revenue to grow in the high teens and Cygnus revenue to rise at a low- to mid-single-digit rate.

However, the company raised its full-year adjusted EBITDA guidance to $33 million to $35 million, representing an expected year-over-year improvement of $64 million to $66 million. It also now expects adjusted gross-margin expansion of more than 1,400 basis points for the year.

Management said it kept revenue guidance unchanged because CDMO projects and large GMP consumables orders can be substantial and their timing depends on customer program schedules. Brust said the company sees growth in smaller and midsized orders and described the revenue outlook as a prudent reflection of potential variability in larger orders.

Maravai provided investors with a new framework for assessing TriLink’s operations, separating the business conceptually into mRNA, CDMO and specialty chemistry categories while continuing to report externally through its TriLink and Cygnus operating segments. Excluding COVID-related CleanCap revenue, management said mRNA represents approximately 35% of expected 2026 revenue and is expected to grow at high-single-digit to low-double-digit rates over time.

About Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source